Principal Investigator: Dr. Kathleen Egan
Department: Cancer Epidemiology
Moffitt Cancer Center, Cancer Epidemiology, 12902 Magnolia Drive, Tampa FL 33612, USATags: 16944, genetics, glioblastoma, Glioma, meningioma, Risk, susceptibility
1a: Brain tumours are a devastating diagnosis. Our focus is inherited genetic susceptibility. In a US-based case-control study, glioma (~1900), meningioma (~500) and a sample of study controls (~1000) are genotyped using the UK Biobank array. The goal is to supplement study controls with unaffected persons from the UK Biobank project genotyped using the same array. These controls will greatly enhance power, especially for study of tumour-specific variants expected to be rare in the general population. Limited questionnaire data will also be requested. The study may offer important new insights in the prevention of brain tumours.
1b: Our project fulfils UK Biobank’s overall goal “… to improve the prevention, diagnosis and treatment of illness and the promotion of health throughout society”. We focus on poorly understood tumours and important contributor to cancer burden in society. (In the US, glioma is the 8th leading cause of cancer death in Caucasian men). We study disease prevention and attempt to identify novel risk factors that may point to lifestyle interventions for risk reduction. We consider genetic risk with prospects for targeted screening and early detection based on high-risk genotypes. New targets for therapy could also emerge.
1c: In this case-control study, we will compare inherited genetic traits in persons with brain tumour and persons with no history of these uncommon tumours. DNA samples were collected from persons enrolled in a large US case-control study of brain tumours (glioma and meningioma). Genotyping is underway for all cases (2,400) and a sample of study controls (1,000). The identical array for genotyping was used for most subjects in the UK Biobank project. The proposal is to supplement study controls with UK Biobank participants which will greatly enhance our power to detect rare brain tumour risk variants.
1d: We will request data for a subset of ~20,000 persons genotyped using the Affymetrix UK Biobank array, with the number requested subject to cost and availability.
In June 2017, we were approved to expand this scope to include “nongenetic risk factors” specifically cell phone use; early life exposures; sleep; reproductive exposures; occupation; analgesic medications; relevant health history (e.g., headache; diabetes); alcohol & smoking; and diet. Many of these exposures have been linked to glioma risk in retrospective studies that are subject to bias, and prospective analyses via the UKBiobank will yield definitive findings. Proposed New Scope – To complement and expand upon our ongoing studies of modifiable risk factors, we are proposing to examine blood biomarkers now available related to inflammation (C-reactive protein, IGF-1, neutrophil-to-lymphocyte ratio and vitamin D) and lipidemia (total cholesterol, lipoproteins and triglyceride).
Last updated Sep 16, 2019